1. P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). (2nd July 2019) Authors: Aparicio, J; Virgili, A; Capdevila, J; Muñoz Boza, F; Álvarez, R; Bosch, C; Cámara, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernández-Yagüe, X; Macías Declara, I; Rodríguez-Salas, N; Vera, R; Taberner, M; Maurel, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The right compound for the right target: tackling RET. (31st May 2018) Authors: Seoane, J; Capdevila, J Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Early evolutionary divergence between papillary and anaplastic thyroid cancers. (10th April 2018) Authors: Capdevila, J; Mayor, R; Mancuso, F M; Iglesias, C; Caratù, G; Matos, I; Zafón, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, J M; Álvarez, C; Recio, J A; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1829TiPA noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC). (23rd October 2018) Authors: Krajewska, J; Robinson, B G; Keam, B; Capdevila, J; Klochikhin, A; Gan, H; Kapiteijn, E; Elisei, R; Partyka, J; Borgman, A E; Schlumberger, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). (23rd October 2018) Authors: Martin-Liberal, J; Pagliuca, F; Hierro, C; Viaplana, C; Muñoz Couselo, E; Capdevila, J; Matos, I; Fariñas Madrid, L; Zamora, E; Braña Garcia, I; Elez Fernandez, E; Ochoa De Olza Amat, M; Azaro, A; Alsina, M; Vieito Villar, M; Fasani, R; Tabernero, J; Garralda, E; Dienstmann, R; Nuciforo, P G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 1315PDevelopment and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study. (23rd October 2018) Authors: Garcia-Carbonero, R; Alonso, V; Capdevila, J; Sanchez Canovas, M; Alonso, T; Benavent, M; Custodio, A; Crespo Herrero, G; Lopez, C; Hernando, J; Riesco Martinez, M C; Escudero, P; Gallego Plazas, J; Marazuela, M; Diaz, J A; Llanos-Munoz, M; La Casta, A; Percovich, J C; Jimenez-Fonseca, P; Carmona... Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 1329PEfficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy. (23rd October 2018) Authors: Hernando Cubero, J; Grande, E; Jimenez Fonseca, P; Villabona, C; Trigo Perez, J M; Martinez Trufero, J; Pajares Bernad, I; Lopez, C; Alonso, T; Biarnes, J; Ramón, T; Cajal, Y; Duran, M; Grau, J J; Arevalo Lobera, S; Mesia Nin, R; Llanos, M; Dalmau Portulas, E; Alvarez, C; Zafon, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 1330PDevelopment and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry. (23rd October 2018) Authors: Thyparambil, S; An, E; Sellappan, S; Wertheimer, E R; Landolfi, S; Capdevila, J; Cecchi, F; Nuciforo, P G; Heaton, R; Hembrough, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Early evolutionary divergence between papillary and anaplastic thyroid cancers. (13th August 2019) Authors: Capdevila, J; Mayor, R; Mancuso, F M; Iglesias, C; Caratú, G; Matos, I; Zafón, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, J M; Álvarez, C V; Recio, J A; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (13th August 2019) Authors: Kulke, M H; Ruszniewski, P; Van Cutsem, E; Lombard-Bohas, C; Valle, J W; De Herder, W W; Pavel, M; Degtyarev, E; Brase, J C; Bubuteishvili-Pacaud, L; Voi, M; Salazar, R; Borbath, I; Fazio, N; Smith, D; Capdevila, J; Riechelmann, R P; Yao, J C Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1846 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗